home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

49.85 -0.55 (-1.09%)

Streaming Delayed Price Updated: 3:59 PM EDT, Apr 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

36 37 Next >

Genentech's Tecentriq Plus Avastin Combo Cuts Risk of Cancer Returning In Early-Stage Liver Cancer ↗

January 19, 2023

Via Benzinga

Genentech’s Tecentriq Plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People With Certain Types of Early-Stage Liver Cancer in a Phase III Trial

January 19, 2023

From Genentech

Via Business Wire

Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December ↗

January 17, 2023

On December 14th, the Federal Reserve hiked its key interest rate by 50 basis points. This was the first deceleration in rate hike increases in 2022; between March and November 2022, the interest rate...

Via Benzinga

Europe Approves Xofluza, Roche's Revolutionary Influenza Antiviral with New Mechanism ↗

January 12, 2023

Via Benzinga

Biotech Giant Regeneron Hit As Eylea Gives Ground To Avastin ↗

January 09, 2023

Regeneron Pharmaceuticals says sales of linchpin Eylea drug have been negatively impacted rival drug Avastin. REGN stock plunged on the news.

Via Investor's Business Daily

Twitter Hackers Stole More Than 200M Emails, Delta Air Lines To Offer Free Wi-Fi, Bed Bath & Beyond's Bankruptcy Coming Sooner Than Expected: Top Stories Today ↗

January 06, 2023

Benzinga

Via Benzinga

Roche's Investigational Lymphoma Candidate Goes Under FDA Priority Review ↗

January 06, 2023

Via Benzinga

FDA Grants Priority Review to Genentech’s Bispecific Antibody Glofitamab for People With Relapsed or Refractory Large B-Cell Lymphoma

January 06, 2023

From Genentech

Via Business Wire

Can The No. 1 Pharma Stock, Merck, Continue Its Blazing Run In 2023? ↗

January 05, 2023

Merck has a number of efforts in the works to help avoid a Keytruda generics pitfall.

Via Investor's Business Daily

Better Large-Cap Buy: Roche Holding or Gilead Sciences Stock? ↗

January 02, 2023

Which of these companies is better able to replace declining COVID-19-related sales?

Via The Motley Fool

Big Health Care Stocks to Watch in the New Year

December 29, 2022

Here are three health care stocks to watch as the New Year begins. Two have a moderate Buy rating while one is a Hold, for now.

Via MarketBeat

The Battles Brewing That Could Stoke Already Red-Hot Eli Lilly Stock ↗

December 28, 2022

Investors are closely watching two key spaces that could spark Lilly stock.

Via Investor's Business Daily

Roche's Follicular Lymphoma Therapy Scores FDA Approval ↗

December 23, 2022

Via Benzinga

FDA Approves Genentech’s Lunsumio, a First-in-Class Bispecific Antibody, to Treat People With Relapsed or Refractory Follicular Lymphoma

December 22, 2022

From Genentech

Via Business Wire

FDA Approves Roche's Tocilizumab As First Monoclonal Antibody For COVID-19 Treatment ↗

December 22, 2022

Via Benzinga

Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023? ↗

December 22, 2022

Crispr and Vertex are working toward the first submissions for a CRISPR-based product.

Via Investor's Business Daily

Top Biotech Companies Are Making Steady Progress In Developing Treatments To Fight Alzheimer’s Disease ↗

December 21, 2022

The estimated cost of Alzheimer's disease and related dementia (ADRD) care in 2021 was $355 billion. Investing in the top companies that are making steady progress toward developing a treatment for...

Via Talk Markets

FDA Approves Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults

December 21, 2022

From Genentech

Via Business Wire

Gilead Sciences (GILD) Stock Falls on Lung Cancer Drug Data ↗

December 20, 2022

Although Gilead Sciences produced meaningful results regarding a lung cancer drug test, the competitive shortfall hurt GILD stock.

Via InvestorPlace

Arcus, Gilead Disappoint As Lung-Cancer Regimen Lags Rival Roche ↗

December 20, 2022

Gilead and Arcus toppled Tuesday after their lung-cancer regimen trailed a rival concoction from Roche.

Via Investor's Business Daily

Eli Lilly Expects Enduring Growth, Despite Immediate Challenges

December 19, 2022

Eli Lilly & Co may be struggling with supply-side issues but new partnerships and a healthy dividend are helping to keep up their momentum

Via MarketBeat

OTC Market Group’s Most Active List In November: A Dive Into The Names Experiencing Volume Changes

December 14, 2022

The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 5.56% in November, recording two subsequent monthly increases for the first time in 2022. The Fidelity NASDAQ Composite Index ETF (NASDAQ: ONEQ)...

Via TheNewswire.com

Topics ETFs Economy Stocks

OTC Market Group's Most Active List In November: A Dive Into The Names Experiencing Volume Changes ↗

December 13, 2022

The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 5.56% in November, recording two subsequent monthly increases for the first time in 2022.

Via Benzinga

Roche Presents New Data Demonstrating Potential Benefit Of Two Lymphoma Candidates ↗

December 12, 2022

Via Benzinga

Spark Therapeutics Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A

December 12, 2022

From Spark Therapeutics, Inc.

Via GlobeNewswire

Genentech Presents New Data Demonstrating the Potential of Glofitamab and Mosunetuzumab as Fixed-Duration, Off-The-Shelf Treatment Options for Lymphoma

December 12, 2022

From Genentech

Via Business Wire

Broadcom-Vmware Deal Draws European Regulatory Attention, Rivian Pauses Mercedes-Partnered EV Van Plans For Europe, Credit Suisse Issued Loan On Suspicious Bills: Top Stories Monday, Dec. 12 ↗

December 12, 2022

Reuters Broadcom's Vmware Draws More Regulatory Attention, This Time From EU

Via Benzinga

After 16 Years, Roche's Pharma Division Head Decides To Step Down ↗

December 12, 2022

Via Benzinga

Genentech Presents New and Updated Data for Polivy in Previously Untreated Diffuse Large B-Cell Lymphoma at ASH 2022

December 11, 2022

From Genentech

Via Business Wire

Interim Data From Phase III Study Presented at ASH 2022 Show Hemlibra (emicizumab-kxwh) Achieved Meaningful Bleed Control in Infants From Birth

December 11, 2022

From Genentech

Via Business Wire

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com